SEC Form 4 · accession 0000905148-26-003499
Acrivon Therapeutics, Inc. · ACRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam D. Levy
Officer — Chief Financial Officer
Period of report
Aug 4, 2026
Accepted (ET)
Aug 6, 2026 · 4:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001781174
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 4, 2026 | S | 1,142 | $1.57 | D | 66,008 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.